PL2858647T3 - Inhibitory receptora h4 do leczenia szumów usznych - Google Patents

Inhibitory receptora h4 do leczenia szumów usznych

Info

Publication number
PL2858647T3
PL2858647T3 PL13727899T PL13727899T PL2858647T3 PL 2858647 T3 PL2858647 T3 PL 2858647T3 PL 13727899 T PL13727899 T PL 13727899T PL 13727899 T PL13727899 T PL 13727899T PL 2858647 T3 PL2858647 T3 PL 2858647T3
Authority
PL
Poland
Prior art keywords
receptor inhibitors
treating tinnitus
tinnitus
treating
inhibitors
Prior art date
Application number
PL13727899T
Other languages
English (en)
Inventor
Éric WERSINGER
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of PL2858647T3 publication Critical patent/PL2858647T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13727899T 2012-06-08 2013-06-10 Inhibitory receptora h4 do leczenia szumów usznych PL2858647T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657460P 2012-06-08 2012-06-08
EP13727899.0A EP2858647B1 (en) 2012-06-08 2013-06-10 H4 receptor inhibitors for treating tinnitus
PCT/EP2013/061936 WO2013182711A1 (en) 2012-06-08 2013-06-10 H4 receptor inhibitors for treating tinnitus

Publications (1)

Publication Number Publication Date
PL2858647T3 true PL2858647T3 (pl) 2018-10-31

Family

ID=48579084

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13727899T PL2858647T3 (pl) 2012-06-08 2013-06-10 Inhibitory receptora h4 do leczenia szumów usznych

Country Status (12)

Country Link
US (1) US9688989B2 (pl)
EP (2) EP2858647B1 (pl)
JP (2) JP6185574B2 (pl)
CN (1) CN104582703A (pl)
CY (1) CY1120732T1 (pl)
DK (1) DK2858647T3 (pl)
ES (1) ES2683380T3 (pl)
HU (1) HUE039713T2 (pl)
PL (1) PL2858647T3 (pl)
PT (1) PT2858647T (pl)
SI (1) SI2858647T1 (pl)
WO (1) WO2013182711A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201729810A (zh) * 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
TWI831855B (zh) 2018-10-26 2024-02-11 日商大鵬藥品工業股份有限公司 新穎吲唑化合物或其鹽
CA3148745A1 (en) * 2019-08-29 2021-03-04 Xiaolun Wang Kras g12d inhibitors
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021106230A1 (ja) 2019-11-29 2021-06-03 大鵬薬品工業株式会社 新規なフェノール化合物又はその塩
CN114555565B (zh) * 2019-12-13 2024-03-05 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
WO2022109487A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6093417A (en) 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
GB0101223D0 (en) 2001-01-17 2001-02-28 Pfizer Ltd Histamine receptor antagonists
AU2002336273A1 (en) 2001-03-09 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
AU2003274956A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
JP4596915B2 (ja) 2002-09-06 2010-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チエノピロリルおよびフラノピロリル化合物並びにヒスタミンｈ４受容体リガンドとしてのそれらの使用
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US20040105856A1 (en) 2002-12-02 2004-06-03 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
US20050090527A1 (en) 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
KR20060111466A (ko) 2003-09-30 2006-10-27 얀센 파마슈티카 엔.브이. 퀴녹살린 화합물
NZ546259A (en) 2003-09-30 2009-05-31 Janssen Pharmaceutica Nv Benzoimidazole compounds
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
MXPA06011021A (es) 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
JP2008519794A (ja) 2004-11-11 2008-06-12 アージェンタ・ディスカバリー・リミテッド ピリミジン化合物
JP2008520644A (ja) 2004-11-24 2008-06-19 ファイザー・インク オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
BRPI0615880A2 (pt) 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
EP1767537A1 (en) 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007090853A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders
EP1829879A1 (en) 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007090854A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007117399A2 (en) 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
EP2010172B1 (en) 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
WO2007120690A2 (en) 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
PE20080520A1 (es) 2006-07-11 2008-06-13 Janssen Pharmaceutica Nv Derivados de benzofuro- y benzotienopirimidina como moduladores del receptor de histamina h4
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008074445A1 (en) 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
WO2008122378A1 (en) 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
SE531373C2 (sv) 2007-06-27 2009-03-17 Syntune Ab Mach Zehndermodulator
WO2009022551A1 (ja) 2007-08-10 2009-02-19 Ube Industries, Ltd. 芳香族化合物の製造方法
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
PE20090978A1 (es) 2007-10-30 2009-07-13 Palau Pharma Sa DERIVADOS DE FURO {3,2-d} PIRIMIDINA
PE20091035A1 (es) 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
FR2924344B1 (fr) 2007-12-04 2010-04-16 Pf Medicament Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
WO2009077608A1 (en) 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
US8431580B2 (en) 2007-12-21 2013-04-30 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
WO2009107767A1 (ja) 2008-02-29 2009-09-03 大日本住友製薬株式会社 Ｈ４受容体アンタゴニスト作用を有する新規２環性ピリミジン誘導体
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
TW200951136A (en) 2008-03-17 2009-12-16 Palau Pharma Sa Furo[3,2-d]pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2009134726A1 (en) 2008-04-28 2009-11-05 Abbott Laboratories Substituted pyrimidine derivatives as histamine h4 receptor ligands
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
EP2201982A1 (en) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US20120077883A1 (en) 2009-03-31 2012-03-29 De Barros Coelho Claudia Couto Treatment of tinnitus and associated auditory dysfunctions
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
EP2447263A1 (en) 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2491930A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
WO2013060881A1 (en) 2011-10-27 2013-05-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Pyridopyrimidines and their therapeutic use

Also Published As

Publication number Publication date
CN104582703A (zh) 2015-04-29
JP2015520180A (ja) 2015-07-16
SI2858647T1 (sl) 2018-11-30
CY1120732T1 (el) 2019-12-11
HK1209321A1 (en) 2016-04-01
DK2858647T3 (en) 2018-08-20
EP2858647B1 (en) 2018-05-23
JP6185574B2 (ja) 2017-08-23
ES2683380T3 (es) 2018-09-26
US9688989B2 (en) 2017-06-27
JP2017214414A (ja) 2017-12-07
PT2858647T (pt) 2018-10-03
US20150176010A1 (en) 2015-06-25
HUE039713T2 (hu) 2019-02-28
EP2858647A1 (en) 2015-04-15
WO2013182711A1 (en) 2013-12-12
EP3378476A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
IL281178A (en) Methods of treating or preventing cholesterol related disorders
EP2768443A4 (en) METHODS AND DEVICES FOR TREATING HYPERTENSION
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
AP4045A (en) Irradiation apparatus
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
PT2858647T (pt) Inibidores do recetor h4 para tratamento de tinido
ZA201906339B (en) Methods for treating pruritus
ZA201208219B (en) Method for treating wasterwater
ZA201407904B (en) Nampt inhibitors
IL228644A0 (en) Cancer treatment methods
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
LT2852602T (lt) Oligonukleotidų konjugavimo būdas
HUE050799T2 (hu) Berendezés szerves massza kezelésére
IL235919A0 (en) inhibitors of fbxo3
EP2916767A4 (en) DEVICES FOR TREATING TEETH NECKS
PL2760411T3 (pl) Urządzenie do przeciwdziałania zakrzepicy
EP2855706A4 (en) BIOMARKER FOR TREATMENT RESULTS
HUE044767T2 (hu) Módszerek és eljárás szolid tumorok kezelésére
EP2919856A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
EP2846703A4 (en) DEVICE AND METHOD FOR TREATING A DIVERTICULAR DISEASE
EP2816126A4 (en) THERMAL TREATMENT METHOD
GB201105523D0 (en) Treatment method
EP2822545A4 (en) TREATMENT OF HIGH RATE OF CHOLESTEROL
ZA201407215B (en) Method for emulsion treatment